Pierre K. Isogai

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial

Nicole Mittmann, H. Au, D. Tu et al. · JNCI Journal of the National Cancer Institute · 2009 · 141 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document

Nicole Mittmann, William K. Evans, A. Rocchi et al. · Journal of Clinical Oncology · 2009 · 80 citations

Social Sciences, Oncology, Pharmacoeconomics +16

Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer

Penelope A. Bradbury, Dongsheng Tu, Lesley Seymour et al. · JNCI Journal of the National Cancer Institute · 2010 · 76 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +16

Derivation of Utility Values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire Values in Lung Cancer

Raymond Jang, Pierre K. Isogai, Nicole Mittmann et al. · Journal of Thoracic Oncology · 2010 · 65 citations · Full text

Pharmacy, Oncology, Health Assessment +14

Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis Against Febrile Neutropenia in Lymphoma Patients

Nina Lathia, Pierre K. Isogai, Carlo DeAngelis et al. · JNCI Journal of the National Cancer Institute · 2013 · 37 citations · Full text

Medicine, Oncology, Pharmacoeconomics +10